Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2
Patent disclosure · 2017
- What the patent describes
- Patent chemistry and preclinical examples
- Reported evidence
- The description enumerates NGF and BDNF analogue series, but the granted US claims specifically identify a Ser-Lys-based dimer rather than every named candidate. GK-1/GK-2 and GSB-104 experiments remain preclinical and include identity or outcome ambiguities.
BDNF-model behavior · GSB-106 and imipramine reduced immobility; GBK-201 and GBK-108 increased it · Different molecules; the unfavorable direction is retained
Reported patent results
Findings described in words
Experimental effects differ by candidate: some dimers were protective or antidepressant-like, while some monomers had unfavorable effects.
Large NGF/BDNF-mimetic patent program with numerous cell and animal comparisons; the granted US claims are narrower than the experimental catalogue.
Population or model Patent chemistry and preclinical examples
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| BDNF-model behavior | GSB-106 and imipramine reduced immobility; GBK-201 and GBK-108 increased it | Different molecules; the unfavorable direction is retained |
| Candidate identity and viability | Some monomeric mimetics reduced neuronal viability; dimeric results were more favorable | Candidate-specific findings, not a class-wide clinical effect |
| Reporting conflict | GSB-104 descriptions and GK-2f structure mapping require reconciliation | No single pooled efficacy percentage inferred from inconsistent examples |
The title and broad description do not mean every experimental candidate is within the granted claims. Cell survival and behavioral proxies do not establish clinical antidepressant or neuroregenerative efficacy.
Source for these results ↗ · Reviewed 2026-11-06
Patent claims and provenance
Platform context. The title refers to NGF and BDNF mimetics, but the granted US claims specifically identify a Ser-Lys-based dimer. This is not a grant to every GK, GSB, GBK or GTS candidate.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- US9683014B2 ↗ · 2017-06-20
- Earliest priority / filing
- 2009-02-16 / 2014-08-15
- Original applicant / assignee
- Uchrezhdenie Rossiiskoi Akademii Meditsynskikh Nauk Nauchno-Issledovatelsky Institut Farmakologii Imeni Vvzakusova Ramn
- Indexed status
- Expired - Fee Related · checked 2026-11-06
- Patent family
- 42561958 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Dipeptide mimetics of NGF and BDNF neurotrophins
Inventors: Sergey Borisovich Seredenin; Alexandrovna Tatyana GUDASHEVA.
US9683014B2 · US20110312895A1 · EP2397488B1 · CN102365294B · RU2410392C2 · WO2010093284A1
Study limitations and source details
Study limitations
- Patent proposals are not established clinical uses.
- Resolve code/structure ambiguities and assay-specific contradictions before interpreting activity.
Source details
Selected original-source text checked; full methodological review pending.
Selected text reviewed
Sources checked
Citation
Author unconfirmed. Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2 Primary source linked above
Related compounds
NGF mimetics: GK & GTS series
A family of experimental peptides designed from exposed loops of nerve growth factor. Related structures can differ in cell survival, differentiation and pain responses.
BDNF mimetics: GSB, GBK & GTS
Small synthetic peptides designed to mimic parts of brain-derived neurotrophic factor (BDNF), a protein involved in nerve-cell survival and signaling.